- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05909436
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
A Phase I/II Study Evaluating the Safety, Tolerability and Preliminary Efficacy of GLS-012 Monotherapy and in Combination With GLS-010 in Patients With Advanced Solid Tumors After Progression on Standard Treatment (Triumph-01)
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Jun Guo, MD
- Phone Number: +86-010-88121122
- Email: guoj307@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients who are willing to sign the informed consent form;
- Aged 18-75 years, male or female;
- Histologically confirmed diagnosis of a solid tumor;
- Patients with advanced solid tumors after progression on standard treatment;
- Subjects must have at least 1 measurable target lesion according to RECIST version 1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;
- Life expectancy more than 12 weeks;
- Adequate organ function and bone marrow function as indicated by the screening assessments in the screening period;
- Women of childbearing potential must use highly effective contraception during the study period and at least 6 months after the last study drug administration, and must have a negative blood pregnancy test within 3 days before study enrollment.
Exclusion Criteria:
- Patients with irAEs of grade ≥ 3 in the previous immunotherapy, and the AEs of the last anti-tumor treatment have not recovered to grade ≤ 1, except for hypothyroidism/hyperthyroidism and dermatitis that have recovered to grade ≤ 2, and AEs with no safety risks judged by the investigators, for example, alopecia.
- Patients with primary or secondary immunodeficiency, or patients who are receiving long-term systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before randomization.
- Use of corticosteroids or other immunosuppressants for systemic treatment within 14 days before the first study drug administration;
- Known central nervous system (CNS) metastases;
- Patients with severe hypersensitivity to macromolecular protein preparations/monoclonal antibodies in the past.
- Patients with other malignant tumors within 5 years before screening, except cured cervical carcinoma in situ and cured skin basal cell carcinoma.
- Cardiac clinical symptoms or diseases that are not well controlled.
- Known hereditary or acquired bleeding and thrombosis tendency.
- Patients with congenital or acquired immunodeficiency disorders (such as HIV-infection), or a history of organ transplantation.
- Patients complying with any of hepatitis B surface antigen (HBsAg) positive and HBV-DNA copies being more than 2500 copies/ml (or 500 IU/ml); or positive HCV-RNA;
- Patients with poor compliance or other conditions that are not suitable to participate in the clinical trial, as considered by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation and expansion of GLS-012 monotherapy and combination with GLS-010
|
In the dose escalation stage of GLS-012 monotherapy, RP2D will be determined. All subjects will receive GLS-012 intravenously Q3W. In the expansion stage of GLS-012 monotherapy, subjects will receive up to 17 doses of GLS-012 at the RP2D administered Q3W. In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W. In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W. In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W. In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with a Dose-Limiting Toxicity (DLT) and MTD in the dose escalation stage
Time Frame: Up to 21 days after the first dose
|
Up to 21 days after the first dose
|
Number of participants with treatment-related adverse events of GLS-012 monotherapy and in combination with GLS-010 in the expansion stage as assessed by CTCAE V5.0
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease control rate (DCR)
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
Time to response (TTR)
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
Objective response rate (ORR)
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
Duration of response (DOR)
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
Overall survival (OS)
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
Maximum plasma concentration (Cmax) of GLS-012 monotherapy and in combination with GLS-010
Time Frame: Up to approximately 4.5 months
|
Up to approximately 4.5 months
|
Elimination half-life (T1/2) of GLS-012 monotherapy and in combination with GLS-010
Time Frame: Up to approximately 4.5 months
|
Up to approximately 4.5 months
|
Preliminary anti-tumor activity: Duration of response (DOR), time to response (TTR), progression free survival (PFS), overall survival (OS)
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
Progression free survival (PFS)
Time Frame: Up to approximately 24 months
|
Up to approximately 24 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Receptor occupancy (RO) of GLS-012 in the dose escalation stage of GLS-012 monotherapy
Time Frame: Up to approximately 4.5 months
|
Up to approximately 4.5 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLS-012-11
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on GLS-012
-
Guangzhou Gloria Biosciences Co., Ltd.Not yet recruitingAdvanced Non-Small Cell Lung CancerChina
-
GeneOne Life Science, Inc.Active, not recruitingCOVID-19 | HealthyPuerto Rico, United States
-
Guangzhou Gloria Biosciences Co., Ltd.Not yet recruitingRecurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Classic Hodgkin's Lymphoma
-
GeneOne Life Science, Inc.Active, not recruitingSARS-CoV Infection | PneumonitisKorea, Republic of, Puerto Rico, United States, Bulgaria, North Macedonia
-
GeneOne Life Science, Inc.TerminatedSARS-CoV 2 | InfectionUnited States
-
Erchonia CorporationCompleted
-
Keros Therapeutics, Inc.RecruitingPulmonary Arterial HypertensionUnited States, Australia
-
GeneOne Life Science, Inc.Not yet recruitingSinusitis ChronicUnited States
-
Raziel Therapeutics Ltd.University of ArizonaCompletedDercum Disease | LipedemaUnited States
-
Raziel Therapeutics Ltd.Completed